Matthew Brook
Clinical Research Fellow (TWO Study)
Recent publications
-
Late Treatment With Autologous Expanded Regulatory T-cell Therapy After Alemtuzumab Induction Is Safe and Facilitates Immunosuppression Minimization in Living Donor Renal Transplantation.
Journal article
Brook MO. et al, (2024), Transplantation, 108, 2278 - 2286
-
A GMP Protocol for the Manufacture of Tregs for Clinical Application.
Chapter
O'Neil A. et al, (2023), 2559, 205 - 227
-
Transplantation Without Overimmunosuppression (TWO) study protocol: a phase 2b randomised controlled single-centre trial of regulatory T cell therapy to facilitate immunosuppression reduction in living donor kidney transplant recipients.
Journal article
Brook MO. et al, (2022), Bmj open, 12
-
“Virtual ward” community outreach support for COVID ‐19‐positive hemodialysis patients may delay but not prevent subsequent admission to hospital: A single‐center retrospective case–control pilot study
Journal article
Gaied J. et al, (2021), Hemodialysis international
-
Towards regulatory cellular therapies in solid organ transplantation.
Journal article
Bottomley MJ. et al, (2021), Trends immunol